Effects of Olmesartan Medoxomil an Angiotensin II Type 1 Receptor Antagonist, on Plasma Concentration of B-Type Natriuretic Peptide, in Hypertensive Patients with Type 2 Diabetes Mellitus

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical drug investigation

• Publication date

  2011-03-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/11586510-000000000-00000PMID 21184621
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Renin–angiotensin–aldosterone system blockade for cardiovascular diseases: current status

  2010cited by this paper
• Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study

  2009cited by this paper
• Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state.

  2008cited by this paper
• Angiotensin II receptor antagonism reverts the selective cardiac BNP upregulation and secretion observed in myocarditis.

  2008cited by this paper
• Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: a comparative study.

  2007cited by this paper
• Feasibility of treating prehypertension with an angiotensin-receptor blocker.

  2006cited by this paper
• Epidemic obesity and type 2 diabetes in Asia.

  2006cited by this paper
• Molecular Mechanism Underlying Inverse Agonist of Angiotensin II Type 1 Receptor*

  2006cited by this paper
• Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study

  2006cited by this paper
• Update on microalbuminuria as a biomarker in renal and cardiovascular disease

  2006cited by this paper
• Characterization of plasma brain natriuretic peptide level in patients with type 2 diabetes.

  2005cited by this paper
• Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction.

  2005cited by this paper
• Effects of olmesartan medoxomil as an angiotensin II-receptor blocker in chronic hypoxic rats.

  2005cited by this paper
• Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure

  2005cited by this paper
• Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance.

  2004cited by this paper
• Increased Plasma Concentration of Natriuretic Peptides by Selective &bgr;1-Blocker Bisoprolol

  2003cited by this paper
• Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension

  2001cited by this paper
• Plasma brain natriuretic peptide levels in normotensive noninsulin-dependent diabetic patients with microalbuminuria.

  1999cited by this paper
• Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections

  1998cited by this paper
• Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction.

  1997cited by this paper
• The natriuretic-peptide family.

  1997cited by this paper
• Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure

  1994cited by this paper
• Brain natriuretic peptide in plasma, atria, and ventricles of vasopressin- and phenylephrine-infused conscious rats.

  1994cited by this paper
• Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors.

  1992cited by this paper
• Molecular biology and biochemistry of the natriuretic peptide system. I: Natriuretic peptides.

  1992cited by this paper
• Effects of amlodipine on urinary sodium excretion, renin-angiotensin-aldosterone system, atrial natriuretic peptide and blood pressure in essential hypertension.

  1991cited by this paper
• Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide.

  1991cited by this paper

• Comparing the effect of Angiotensin-Converting Enzyme Inhibitors versus Angiotensin Receptor Blockers in heart failure patients with type 2 diabetes mellitus: a systematic review

  2019cites this paper
• In Vitro Antidiabetic Effects of Isolated Triterpene Glycoside Fraction from Gymnema sylvestre

  2018cites this paper
• Usage of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in diabetic hypertensive patients-A Review

  2018cites this paper
• Practical efficacy of olmesartan versus azilsartan in patients with hypertension: a multicenter randomized-controlled trial (MUSCAT-4 study)

  2017cites this paper
• Comparison of valsartan and benazepril when combined with atorvastatin in protecting patients with early cardio-renal syndrome (CRS).

  2015cites this paper
• Antihypertensive Efficacy of the Losartan/Hydrochlorothiazide Combination and its Effect on Plasma B- Type Natriuretic Peptide in Hypertensive Patients Uncontrolled by Angiotensin II Type 1 Receptor Antagonist-Based Therapy

  2012cites this paper
• Olmesartan Medoxomil Treatment Is Associated with Decreased Plasma B-Type Natriuretic Peptide Levels in Patients on Hemodialysis

  2012cites this paper
• Efficacy and Effect on Plasma B-type Natriuretic Peptide Concentration of Losartan-hydrochlorothiazide for Hypertension Uncontrolled by Losartan-based Therapy: Subanalysis of a Multicentre Prospective Observational Study

  2012cites this paper